Skip to main content
. 2022 Jun 28;11(23):4575–4587. doi: 10.1002/cam4.4845

FIGURE 3.

FIGURE 3

Anti‐tumor response of OncoAd in the CT26 mouse model. (A) Immunohistochemical staining for CD45, CD4, and CD8 in the tumor after OncoAd therapy. (B–D) Quantification of positive cells via ImageJ software following CD45 (B), CD8 (C), and CD4 (D) staining (n = 3, *p < 0.05 and **p < 0.01). (E–I) The proportion of tumor‐infiltrating immune cells treated with intratumor OncoAd. Representative contour plots of CD4+ and CD8+ T cells (E) in the CRC mouse model (left); the percentages of positive CD4+ and CD8+ T cells (F, G) are indicated on the right. Analysis of the phenotypes of CD45+ T cells (H) and CD3+ T cells (I) after OncoAd therapy. (J, K) Representative contour plots of PD‐1 (J) and Tim‐3 expression (K) of CD8+ T cells in the CRC mouse model. Significance is indicated as *p < 0.05 or **p < 0.01.